---
title: Blood Spotlight Review on Gene Therapy for Sickle Cell Disease
date: '2024-01-30'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38289232/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240130170640&v=2.18.0
source: Blood
description: The root cause of sickle cell anemia has been known for seven decades,
  yet no curative therapies have been available other than allogeneic bone marrow
  transplantation, applicability is limited. Two potentially curative therapies based
  on gene therapy and gene editing strategies are about to enter the final stages
  of the FDA approval process. This review surveys the nature of these therapies and
  the opportunities and issues raised by the prospect of definitive genetically based
  therapies ...
disable_comments: true
---
The root cause of sickle cell anemia has been known for seven decades, yet no curative therapies have been available other than allogeneic bone marrow transplantation, applicability is limited. Two potentially curative therapies based on gene therapy and gene editing strategies are about to enter the final stages of the FDA approval process. This review surveys the nature of these therapies and the opportunities and issues raised by the prospect of definitive genetically based therapies ...